Quantbot Technologies LP Buys New Shares in Xeris Biopharma Holdings, Inc. $XERS

Key Points

• Quantbot Technologies LP acquired 54,107 shares of Xeris Biopharma Holdings, Inc., valued at approximately $297,000, during the first quarter.
• Hedge fund Invesco Ltd. increased its stake in Xeris Biopharma by 1,387.8%, owning over 1 million shares worth $5.6 million after acquiring a significant number of additional shares.
• Xeris Biopharma's stock price recently opened at $7.99, with a market cap of $1.29 billion and a 12-month high of $8.02.

Quantbot Technologies LP acquired a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 54,107 shares of the company's stock, valued at approximately $297,000.

Several other large investors have also bought and sold shares of the business. Russell Investments Group Ltd. lifted its holdings in Xeris Biopharma by 632.7% in the first quarter. Russell Investments Group Ltd. now owns 131,687 shares of the company's stock valued at $723,000 after buying an additional 113,713 shares during the period. Informed Momentum Co LLC lifted its holdings in Xeris Biopharma by 320.3% in the first quarter. Informed Momentum Co LLC now owns 934,646 shares of the company's stock valued at $5,131,000 after buying an additional 712,269 shares during the period. Knott David M Jr raised its holdings in Xeris Biopharma by 11.0% in the first quarter. Knott David M Jr now owns 1,110,000 shares of the company's stock worth $6,094,000 after purchasing an additional 110,000 shares during the period. Nuveen LLC acquired a new stake in Xeris Biopharma in the first quarter worth $12,240,000. Finally, Aigen Investment Management LP acquired a new stake in Xeris Biopharma in the first quarter worth $92,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have weighed in on XERS shares. Leerink Partners increased their target price on shares of Xeris Biopharma from $7.00 to $9.00 and gave the stock an "outperform" rating in a report on Tuesday, August 19th. Wall Street Zen upgraded shares of Xeris Biopharma from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 9th. HC Wainwright started coverage on shares of Xeris Biopharma in a report on Tuesday, August 12th. They issued a "buy" rating and a $10.00 target price on the stock. Finally, Oppenheimer increased their target price on shares of Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $7.08.

Insider Activity at Xeris Biopharma

In related news, Director John Johnson sold 107,500 shares of the firm's stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $7.32, for a total value of $786,900.00. Following the completion of the transaction, the director owned 833,483 shares of the company's stock, valued at approximately $6,101,095.56. This trade represents a 11.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Dawn Halkuff sold 42,500 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $7.28, for a total transaction of $309,400.00. Following the completion of the transaction, the director directly owned 115,000 shares of the company's stock, valued at approximately $837,200. This trade represents a 26.98% decrease in their position. The disclosure for this sale can be found here. Insiders sold 192,232 shares of company stock worth $1,430,777 over the last three months. 6.47% of the stock is currently owned by insiders.

Xeris Biopharma Trading Down 0.9%

Shares of XERS stock traded down $0.07 during trading hours on Friday, hitting $7.83. 1,513,967 shares of the company were exchanged, compared to its average volume of 3,564,832. The business has a 50 day moving average of $5.87 and a two-hundred day moving average of $5.00. Xeris Biopharma Holdings, Inc. has a 52 week low of $2.48 and a 52 week high of $8.02. The company has a market capitalization of $1.26 billion, a PE ratio of -37.28 and a beta of 0.65.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.02. The company had revenue of $67.71 million for the quarter, compared to the consensus estimate of $64.58 million. On average, research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.